The Patent Finder

Terms ending in 2034

Biodesix, Inc.

Every in-force patent on Biodesix, Inc.'s record whose computed term ends in 2034, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresConfidence
US 10,593,529Mass-Spectral Method for Selection, and De-selection, of Cancer Patients for Treatment with Immune Response Generating Therapies
In force
 · High confidence
Globeimmune, Inc.In forceHigh confidence
US 9,211,314Treatment selection for lung cancer patients using mass spectrum of blood-based sample
In force
 · High confidence
Biodesix Inc.In forceHigh confidence
2 of 2 patents shown. Soonest term end first, then patent number.
1 of these is in force and held by Biodesix, Inc..
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited